These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 29106062)
1. Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells. Chen Y; Sun L; Guo D; Wu Z; Chen W J Gene Med; 2017 Dec; 19(12):. PubMed ID: 29106062 [TBL] [Abstract][Full Text] [Related]
2. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy. Li TS; Yawata T; Honke K Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580 [TBL] [Abstract][Full Text] [Related]
4. Overcoming multidrug resistance in 2D and 3D culture models by controlled drug chitosan-graft poly(caprolactone)-based nanoparticles. Shi WB; Le VM; Gu CH; Zheng YH; Lang MD; Lu YH; Liu JW J Pharm Sci; 2014 Apr; 103(4):1064-74. PubMed ID: 24523221 [TBL] [Abstract][Full Text] [Related]
5. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601 [TBL] [Abstract][Full Text] [Related]
6. Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes. Chen Z; Zhang T; Wu B; Zhang X Int J Nanomedicine; 2016; 11():991-1002. PubMed ID: 27042054 [TBL] [Abstract][Full Text] [Related]
7. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF. Şalva E; Turan SÖ; Eren F; Akbuğa J Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537 [TBL] [Abstract][Full Text] [Related]
8. Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. Hajizadeh F; Moghadaszadeh Ardebili S; Baghi Moornani M; Masjedi A; Atyabi F; Kiani M; Namdar A; Karpisheh V; Izadi S; Baradaran B; Azizi G; Ghalamfarsa G; Sabz G; Yousefi M; Jadidi-Niaragh F Eur J Pharmacol; 2020 Sep; 882():173235. PubMed ID: 32574672 [TBL] [Abstract][Full Text] [Related]
10. HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. Zhao Q; Li Y; Tan BB; Fan LQ; Yang PG; Tian Y PLoS One; 2015; 10(8):e0132746. PubMed ID: 26292288 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of Drug Sensitivity by Knockdown of HIF-1α in Gastric Carcinoma Cells. Zhao Q; Tan BB; Li Y; Fan LQ; Yang PG; Tian Y Oncol Res; 2016; 23(3):129-36. PubMed ID: 26931435 [TBL] [Abstract][Full Text] [Related]
12. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438 [TBL] [Abstract][Full Text] [Related]
13. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Gu J; Al-Bayati K; Ho EA Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051 [TBL] [Abstract][Full Text] [Related]
14. Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles. Li Y; Zhang J; Wang B; Shen Y; Ouahab A Drug Dev Ind Pharm; 2016; 42(5):737-46. PubMed ID: 26472259 [TBL] [Abstract][Full Text] [Related]
15. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852 [TBL] [Abstract][Full Text] [Related]
16. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Yuan X; Shah BA; Kotadia NK; Li J; Gu H; Wu Z Pharm Res; 2010 Jul; 27(7):1285-95. PubMed ID: 20309616 [TBL] [Abstract][Full Text] [Related]
17. 5-flourouracil loaded N,O-carboxymethyl chitosan nanoparticles as an anticancer nanomedicine for breast cancer. Anitha A; Chennazhi KP; Nair SV; Jayakumar R J Biomed Nanotechnol; 2012 Feb; 8(1):29-42. PubMed ID: 22515092 [TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047 [TBL] [Abstract][Full Text] [Related]
19. Effect of small interfering RNA targeting hypoxia-inducible factor-1α on radiosensitivity of PC3 cell line. Huang Y; Yu J; Yan C; Hou J; Pu J; Zhang G; Fu Z; Wang X Urology; 2012 Mar; 79(3):744.e17-24. PubMed ID: 22196409 [TBL] [Abstract][Full Text] [Related]
20. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer. Wen ZM; Jie J; Zhang Y; Liu H; Peng LP Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]